Galectin Therapeutics Inc. logo

Galectin Therapeutics Inc.

NASDAQ:GALT

Overview | Financials
Company Name Galectin Therapeutics Inc.
Symbol GALT
Currency USD
Price 1.32
Market Cap 83,398,260
Dividend Yield 0%
52-week-range 0.73 - 3.78
Industry Biotechnology
Sector Healthcare
CEO Mr. Joel Lewis
Website https://galectintherapeutics.com

An error occurred while fetching data.

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated

Related Stocks

Eyenovia, Inc. logo

Eyenovia, Inc.

EYEN

1.09 USD

Centogene N.V. logo

Centogene N.V.

CNTG

0.325 USD

Augmedix, Inc. logo

Augmedix, Inc.

AUGX

2.345 USD

Viracta Therapeutics, Inc. logo

Viracta Therapeutics, Inc.

VIRX

0.022 USD

Journey Medical Corporation logo

Journey Medical Corporation

DERM

7.47 USD

BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp.

BCTX

5.2 USD

Minerva Surgical, Inc. logo

Minerva Surgical, Inc.

UTRS

0 USD

HCW Biologics Inc. logo

HCW Biologics Inc.

HCWB

6.9 USD

Financials

Numbers are in millions USD

Numbers are in millions USD